Loading data for ETON — first visit, this takes a few seconds.

알림

Eton Pharmaceuticals Inc. (ETON)

NasdaqGM: ETON · 실시간 가격 · USD

62.62

-0.43 (-0.68%)

종가 기준: Aug 26, 2026, 8:00 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.68% (1D)

데이터 없음

매수호가	34.05
시가총액	1.79B
매출 (ttm)	105.59M
순이익 (ttm)	12.69M
	0.87
	0.39
	160.56
	24.27
P/B (ttm)	38.02
P/S (ttm)	16.95
실적 발표일	Nov 12, 2026

매도호가	58.47
거래량	359,805
평균 거래량 (20일)	532,315
시가	63.60
전일 종가	63.05
일중 범위	61.03 - 63.60
52주 범위	14.27 - 66.37
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ETON 소개

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhy...

섹터 Healthcare

IPO 일자 Nov 13, 2018

직원 수 44

상장 거래소 NasdaqGM

티커 ETON

웹사이트 https://www.etonpharma.com

전체 기업 정보

재무 실적

2025년 Eton Pharmaceuticals의 매출은 79.95M로, 전년 39.01M 대비 104.94% 증가했습니다. 순이익은 -4.6M로, 20.35% 증가했습니다.

재무제표

어닝 서프라이즈

Eton Pharmaceuticals가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $24.27M 예상치 하회 $0, 및 40.41% 전년 대비 성장.
EPS 0.43 예상치 상회 0.24, 및 1333.33% 전년 대비 성장.

다음 실적 발표

Eton Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · Investor's Business Daily

TGTX Stock Outperforms 95% of Stocks. Here's Why.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

5일 전 · Investor's Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

6일 전 · Motley Fool

Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript

Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth.

1주 전 · Simply Wall St.

Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance?

Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to ea...

1주 전 · Investor's Business Daily

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance.

2 페이지 중 1

Eton Pharmaceuticals Inc. (ETON)